Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals informs about press release

Glenmark Pharma’s arm gets USFDA’s nod to expand use of RYALTRIS Nasal Spray

The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis

Glenmark Pharmaceuticals informs about press release

Glenmark Pharmaceuticals’ arm launches Olanzapine for Injection

The launch of Olanzapine for Injection underscores its strategic focus on growing a robust injectables portfolio and strengthening its presence within the institutional channel

Glenmark Pharmaceuticals informs about media release

USFDA completes GMP inspection at Glenmark Pharmaceuticals’ Goa facility

At the end of the inspection, the company was issued a Form 483 with six observations

Glenmark Pharmaceuticals’ arm launches Methylene Blue Injection

Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL, of Provepharm SAS

Glenmark Pharmaceuticals informs about press release

Glenmark Pharmaceuticals informs about press release

Glenmark Pharmaceuticals gains as its arm launches Winlevi across key markets in Europe

Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain

Glenmark Pharmaceuticals’ arm launches Winlevi across key markets in Europe

Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain

Glenmark Pharmaceuticals informs about investor presentation

Glenmark Pharmaceuticals inches up as its arm launches Lacosamide Injection

Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals informs about transcript of earnings call